1-11 of 11
Björn Schöttker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Noesslinger, Julia Von Tresckow, Ruediger Liersch, Tobias Gaska, Kathleen Jentsch-Ullrich, Michael Gärtner, Thomas Wolff, Ingo Schwaner, Dominik Wolf, Christof Schneider, Ursula Vehling-Kaiser, Matthias Ritgen, Christian Spoer, Michael J. Eckart, Thomas Decker, Geothy Chakupurakal, Björn Schöttker, Jens Kisro, Janina Stumpf, Eugen Tausch, Stephan Stilgenbauer, Karl-Anton Kreuzer, Sandra Robrecht, Anna Maria Fink, Moritz Fürstenau, Kirsten Fischer, Valentin Goede, Michael Hallek, Barbara F. Eichhorst
Journal: Blood
Blood (2024) 144 (Supplement 1): 4618.
https://doi.org/10.1182/blood-2024-200848
Published: 2024
Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Christian Buske, Efstathios Kastritis, Alexander Grunenberg, Andreas Viardot, Dajana Kaczynski, Heike Mund, Katja Gutmair, Matthias Zingerle, Paul Duewel, Susanne Saussele, Björn Schöttker, Ullrich Graeven, Martin Dreyling, Andrea Kerkhoff, Thomas Weber, Holger F. Hebart, Ralf Ulrich Trappe, Lisa Kaiser, Elke Runge, Jasmin Mark, Simone Ferrero, Daniela Drandi, Falko Fend, Irina Bonzheim, Eva Hoster, Jens Dreyhaupt, Meletios A. Dimopoulos
Journal: Blood
Blood (2024) 144 (Supplement 1): 859.
https://doi.org/10.1182/blood-2024-200604
Published: 2024
Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Moritz Furstenau, Adam Giza, Christof Schneider, Eugen Tausch, Sandra Robrecht, Matthias Ritgen, Jörg Bittenbring, Holger F. Hebart, Björn Schöttker, Anna Lena Illert, Ullrich Graeven, Andrea Stoltefuss, Bernhard Heinrich, Robert Eckert, Anna-Maria Fink, Janina Stumpf, Florian Simon, Kirsten Fischer, Othman Al-Sawaf, Petra Langerbeins, Fanni Kleinert, Jonathan Weiss, Karl-Anton Kreuzer, Anke Schilhabel, Monika Brüggemann, Barbara F. Eichhorst, Stephan Stilgenbauer, Michael Hallek, Paula Cramer
Journal: Blood
Blood (2023) 142 (Supplement 1): 1897.
https://doi.org/10.1182/blood-2023-173707
Published: 2023
Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Deyan Y. Yosifov, Sandra Robrecht, Adam Giza, Armin Riecke, Christof Schneider, Billy Jebaraj, Hassan Jumaa, Marc Young, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer, Eugen Tausch
Journal: Blood
Blood (2023) 142 (Supplement 1): 1903.
https://doi.org/10.1182/blood-2023-179767
Published: 2023
Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (Supplement 1): 199.
https://doi.org/10.1182/blood-2023-180558
Published: 2023
Journal Articles

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations

Clinical Trials & Observations
Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Clemens H. M. Mellink, Anne-Marie van der Kevie-Kersemaekers, Julie Dubois, Julia von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christof Schneider, Christian Bjoern Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Nösslinger, Michael Baumann, Holger Hebart, Tobias Gaska, Josien C. Regelink, Ellen C. Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marcel Spaargaren, Eric Eldering, Stephan Stilgenbauer, Carsten U. Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (5): 446–459.
https://doi.org/10.1182/blood.2023019634
Published: 2023
Includes: Supplemental data
Journal Articles

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Moritz Furstenau, Yvonne Thus, Sandra Robrecht, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Julie M.N. Dubois, Julia Von Tresckow, Michaela Patz, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Michael Baumann, Thomas Noesslinger, Josien Regelink, Ellen C Dompeling, Vesa Lindström, Gunnar Juliusson, Anouk Widmer, Jeroen Simon Goede, Neta Goldschmidt, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Eric Eldering, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Karl-Anton Kreuzer, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 842–845.
https://doi.org/10.1182/blood-2022-164786
Published: 2022
Journal Articles

Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial

Eugen Tausch, Christof Schneider, Moritz Furstenau, Sandra Robrecht, Deyan Yordanov Yosifov, Daniel Mertens, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar da Cunha-Bang, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Clemens-Martin Wendtner, Eric Eldering, Karl-Anton Kreuzer, Matthias Ritgen, Anna-Maria Fink, Kirsten Fischer, Arnon P. Kater, Carsten Utoft Niemann, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 839–841.
https://doi.org/10.1182/blood-2022-163775
Published: 2022
Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 2639.
https://doi.org/10.1182/blood-2021-147790
Published: 2021
Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (Supplement 1): 71.
https://doi.org/10.1182/blood-2021-146161
Published: 2021
Journal Articles

Pulsing with Blast Cell Lysate or Blast-Derived Total RNA Reverses the Dendritic Cell-Mediated Increase in Cytotoxic Activity of Cytokine-Induced Killer Cells Against Human Allogeneic Acute Myelogenous Leukemia Cells.

Bjorn Schottker, MD, Angela Marten, PhD, Carsten Ziske, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD
Journal: Blood
Blood (2004) 104 (11): 4531.
https://doi.org/10.1182/blood.V104.11.4531.4531
Published: 2004